These findings not only reveal a novel therapeutic mechanism involving coordinated SGK1 inhibition and autophagy activation in GBM treatment, but also provide compelling evidence for developing combination therapies targeting these synergistic pathways to overcome therapeutic resistance. Here, SGK1 is linked to glioblastoma.